Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
about
Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Extreme mutational selectivity ...... or BCR-ABL1-positive leukemia.
@en
type
label
Extreme mutational selectivity ...... or BCR-ABL1-positive leukemia.
@en
prefLabel
Extreme mutational selectivity ...... or BCR-ABL1-positive leukemia.
@en
P2093
P2860
P356
P1433
P1476
Extreme mutational selectivity ...... for BCR-ABL1-positive leukemia
@en
P2093
A D Pomicter
M S Zabriskie
M W Deininger
N A Vellore
S L Savage
P2860
P2888
P304
P356
10.1038/LEU.2015.318
P577
2015-11-19T00:00:00Z